Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$86.43 USD
-1.58 (-1.80%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $86.49 +0.06 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for Edwards Lifesciences Corporation falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,645 | 1,215 | 1,467 | 1,403 | 1,517 |
Receivables | 837 | 699 | 665 | 603 | 599 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1,168 | 876 | 727 | 802 | 641 |
Other Current Assets | 386 | 306 | 322 | 283 | 227 |
Total Current Assets | 4,036 | 3,096 | 3,181 | 3,091 | 2,984 |
Net Property & Equipment | 1,749 | 1,633 | 1,547 | 1,395 | 1,060 |
Investments & Advances | 584 | 1,239 | 1,834 | 802 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 586 |
Deferred Charges | 755 | 484 | 247 | 231 | 172 |
Intangibles | 1,682 | 1,450 | 1,492 | 1,505 | 1,504 |
Deposits & Other Assets | 464 | 299 | 111 | 120 | 102 |
Total Assets | 9,363 | 8,293 | 8,503 | 7,237 | 6,488 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 201 | 202 | 205 | 197 | 180 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 969 | 795 | 802 | 670 | 697 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 1,195 | 1,022 | 1,032 | 894 | 902 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 597 | 596 | 596 | 595 | 594 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 778 | 798 | 970 | 1,101 | 784 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,644 | 2,486 | 2,667 | 2,663 | 2,340 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 651 | 646 | 642 | 636 | 218 |
Capital Surplus | 2,274 | 1,969 | 1,700 | 1,438 | 1,623 |
Retained Earnings | 8,992 | 7,590 | 6,068 | 4,565 | 3,742 |
Other Equity | -173 | -255 | -158 | -161 | -156 |
Treasury Stock | 5,025 | 4,144 | 2,417 | 1,904 | 1,279 |
Total Shareholder's Equity | 6,719 | 5,807 | 5,836 | 4,574 | 4,148 |
Total Liabilities & Shareholder's Equity | 9,363 | 8,293 | 8,503 | 7,237 | 6,488 |
Total Common Equity | 6,719 | 5,807 | 5,836 | 4,574 | 4,148 |
Shares Outstanding | 606.50 | 618.20 | 624.30 | 623.20 | 625.70 |
Book Value Per Share | 11.08 | 9.39 | 9.35 | 7.34 | 6.63 |
Fiscal Year End for Edwards Lifesciences Corporation falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 1,645 | 1,864 | 1,509 | 1,254 |
Receivables | NA | 837 | 802 | 817 | 779 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 1,168 | 1,032 | 980 | 914 |
Other Current Assets | NA | 386 | 369 | 341 | 309 |
Total Current Assets | NA | 4,036 | 4,068 | 3,647 | 3,257 |
Net Property & Equipment | NA | 1,749 | 1,681 | 1,662 | 1,646 |
Investments & Advances | NA | 584 | 705 | 856 | 1,067 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 755 | 652 | 611 | 544 |
Intangibles | NA | 1,682 | 1,727 | 1,731 | 1,755 |
Deposits & Other Assets | NA | 464 | 447 | 412 | 294 |
Total Assets | NA | 9,363 | 9,371 | 9,004 | 8,651 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 201 | 191 | 193 | 181 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 969 | 1,024 | 940 | 876 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 1,195 | 1,239 | 1,157 | 1,082 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 597 | 597 | 597 | 597 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 738 | 740 | 845 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 2,644 | 2,644 | 2,558 | 2,589 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 651 | 650 | 649 | 647 |
Capital Surplus | NA | 2,274 | 2,211 | 2,146 | 2,049 |
Retained Earnings | NA | 8,992 | 8,623 | 8,238 | 7,931 |
Other Equity | NA | -173 | -181 | -185 | -171 |
Treasury Stock | NA | 5,025 | 4,576 | 4,401 | 4,394 |
Total Shareholder's Equity | NA | 6,719 | 6,727 | 6,447 | 6,062 |
Total Liabilities & Shareholder's Equity | NA | 9,363 | 9,371 | 9,004 | 8,651 |
Total Common Equity | 0 | 6,719 | 6,727 | 6,447 | 6,062 |
Shares Outstanding | 601.90 | 606.50 | 606.50 | 607.90 | 608.30 |
Book Value Per Share | 0.00 | 11.08 | 11.09 | 10.60 | 9.97 |